The scene
A distributor likes the product. That is good news. But enthusiasm creates a new risk: the product now has a second storyteller.
One version says the product is a workflow improvement. Another says it improves outcomes. Another says it replaces an existing method. Another says it is just an add-on. Each version sounds close enough in the meeting. After a few conversations, the story has drifted.
The wrong frame
The weak frame is, 'Do they understand the deck?' The stronger frame is, 'Can they explain the customer benefit without inventing claims?'
A deck is a map. A distributor handoff page is a flight checklist. It tells the partner what must be said, what must not be improvised, and what question comes back to your team instead of being answered from memory.
Build one distributor handoff page
| Row | Question to answer |
|---|---|
| Target customer | Who is the distributor speaking to? |
| Current alternative | What does that customer use or do today? |
| Buyer benefit | What changes for the customer in practical terms? |
| Public vs. internal knowledge | What is source-supported, and what only your team knows? |
| Open claims | What claims still need review before external use? |
| Escalation question | What question should come back to your team instead of being answered loosely? |
The founder-level move
You do not need every distributor to speak like you. You need every distributor to preserve the same product truth, the same customer benefit, and the same claim boundaries.
A strong partner will welcome that clarity. A risky partner will treat it like friction.
Source ledger
What it can tell you
FDA describes general market-entry steps and broad controls that can include labeling regulations and misbranding restrictions.
What it cannot decide
A specific distributor script, sales strategy, product claim, market readiness, or legal review outcome.
What it can tell you
FDA describes general labeling and intended-use concepts for medical devices.
What it cannot decide
Whether a specific distributor statement is labeling, advertising, consistent with intended use, or acceptable for external use.
What it can tell you
FDA describes misleading labeling and advertising considerations.
What it cannot decide
Whether any specific partner, website, deck, or sales statement is misleading.
What it can tell you
FDA guidance discusses product communications and fact-specific analysis for communications consistent with FDA-required labeling.
What it cannot decide
Whether a specific distributor answer, sales statement, or training statement is consistent with labeling or otherwise appropriate.
Frequently asked questions
Is a distributor handoff page the same as sales training?
No. It is a first control layer: target customer, current alternative, buyer benefit, public/internal knowledge, open claims, and escalation questions. Sales training may later build on it.
Does this decide what a distributor can legally say?
No. It organizes the questions and source boundaries so the company, qualified reviewer, counsel, or regulatory advisor can review the language.
Why does this matter before full launch?
Partner language often becomes customer language. If the first partner story drifts, the company may spend months correcting the wrong category, wrong benefit, or unsupported claim.
Need the distributor version before someone else tells the story?
Request the Market-Ready Sales & Support Pack overview to see how product facts, buyer benefit, and claim boundaries become one distributor handoff artifact.